Carri Geer, Ph.D., is the Senior Vice President, Chief Technology Officer and leads the drug substance, drug product, device and analytical development for Novan’s drug candidates. Additionally, Dr. Geer serves as the technical liaison for collaborative partnerships. Dr. Geer has approximately 10 years of experience in pharmaceutical product development with a background in analytical and bioanalytical chemistry. During her tenure at Novan, Dr. Geer has been responsible for establishing and growing the analytical capabilities of the Company. Prior to joining Novan, Dr. Geer was employed at Merck and bridged the interface between R&D and cGMP analytical testing.
John M. Gay serves as Vice President, Finance and Corporate Controller for Novan, in addition to his role as the Company's Principal Financial Officer and Corporate Secretary. Mr. Gay joined Novan in May 2018 and has previously served as the Company’s Senior Director of Finance and Corporate Controller. Prior to Novan, Mr. Gay held director-level positions, including Director of SEC Reporting, at Valassis Digital (formerly MaxPoint Interactive, Inc.), a digital marketing technology company, from May 2014 through April 2018, and Corporate Controller of Furiex Pharmaceuticals, Inc., a pharmaceutical development company, from June 2010 through May 2014. Prior to joining Furiex, Mr. Gay served as an Audit Senior Manager and in roles of increasing responsibility at Deloitte & Touche and Arthur Andersen, registered public accounting firms, from September 2000 through May 2010. He is a certified public accountant and holds Bachelor’s degrees in Economics and History and a Master of Accounting degree from the University of North Carolina at Chapel Hill.
Tomoko Maeda-Chubachi, MD, PhD, MBA, is the Vice President of Medical Dermatology and provides medical input to help drive the strategy, design and execution of Novan's development programs. Most recently, she served as senior medical director at GSK, leading clinical development projects for psoriasis, atopic dermatitis, pemphigus and androgenic alopecia. Prior to GSK, she held clinical and medical affairs roles at Eli Lilly and Company and Pfizer, Inc. Dr. Maeda-Chubachi was an academic physician and dermatologist for ten years before entering the pharmaceutical industry.
G. Kelly Martin is Chief Executive Officer of Novan, Inc. He served as CEO of Elan, Ireland’s largest indigenous biotech company, from February 2003 until its successful $8.6 Billion sale to Perrigo Company in December 2013. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating and executive responsibilities. Mr. Martin also serves as a non-executive director on a number of public and private company boards and is a co-founder and director of Brandon Point Industries.
Elizabeth Messersmith, Ph.D is the Senior Vice President, Chief Development Officer and is responsible for the oversight of the clinical, medical, statistical, and regulatory activities of the Company. Dr. Messersmith joined Novan as Head of Clinical Operations in May 2018. Most recently, Dr. Messersmith held the position of Senior Vice President, Clinical Operations and Data Management at from Quark Pharmaceuticals, Inc. Prior to Quark, she served in research and development operations and clinical operations roles for Balance Therapeutics, Inc. and previous to that, she was at Elan Pharmaceuticals. Dr. Messersmith has a B.A. and M.A. from the University of Kansas in Human Biology and Physiology, respectively, and a Ph.D. in Biomedical Science from the University of Texas Health Science at Houston.
Andrew Novak serves as Vice President, Accounting and Business Operations of Novan, in addition to his role as the Company's Principal Accounting Officer. Mr. Novak has spent a majority of his accounting career in the life science industry and has significant depth and breadth of experience directing financial and regulatory reporting for public companies. Prior to joining Novan in 2016, Mr. Novak served the as Director, Financial and SEC Reporting at Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company developing anti-infective therapies, from 2014 to 2016. Before joining Scynexis, Mr. Novak was a Financial Audit Manager at Deloitte and a Technical Manager at the AICPA. Mr. Novak received a M.S. in Accounting and a B.S. in Business Administration and Finance from the University of North Carolina at Wilmington and is a Certified Public Accountant.
Tim O’Sullivan, JD, MBA, is the Vice President of Intellectual Capital and spearheads the strategic development of Novan’s intellectual property portfolio. He manages Novan’s licensing strategy and is responsible for building the Company’s robust barriers to entry. Mr. O’Sullivan has more than 20 years of experience in developing intellectual property portfolios. Before joining Novan, Mr. O’Sullivan was the director of intellectual property and business development for LED Lighting Solutions at Cree, Inc.
Paula Brown Stafford, MPH, is the President and Chief Operating Officer of Novan responsible for the translation of Novan's nitric oxide technology into druggable assets across a range of therapeutic areas. Prior to joining Novan, she served as president of clinical development at Quintiles (now QuintilesIMS), where she was responsible for all Phase I-IV clinical development operations globally, reaching $3 billion in annual revenue. In addition to her role at Novan, Ms. Stafford continues to participate in other professional activities, including serving as a director at Health Decisions, Inc. and adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill, and also maintains her third-party consulting business. She was named as one of the 10 top women in biotech by FierceBiotech in 2012, recognized as a Distinguished Alumna at UNC Chapel Hill in 2016, and recently designated an NACD Governance Fellow. She holds a Bachelor of Science and a Masters in Public Health, both from The University of North Carolina at Chapel Hill, with her specialization in Biostatistics.
Elizabeth (Liz) Troll, MS, is the Vice President of Quality Assurance and is responsible for the direction and execution of the Company’s Quality Management System. Ms. Troll joined Novan post her leadership role within IQVIA as Senior Director and Head of the Compliance and Quality Assurance leads. Those roles focused on the strategic alliance management and daily operations delivery for customer accounts for Global Quality Assurance and Healthcare Compliance programs. This global focus will be the baseline for the future development of the Novan quality systems. Ms. Troll chairs Novan’s Compliance Committee. MS. Troll has a B.S. in Chemistry from the University of Mary Washington and a M.S. from the School of Pharmacy at St. John’s University.
Chris Wilson, MS, is the Vice President of Product Operations and is responsible for the oversight of GMP manufacturing, quality control of manufactured products and the Company’s facility. During his tenure at Novan, Mr. Wilson has led the quality control laboratory and inventory control function for raw materials and manufactured products. Prior to joining Novan in 2015, Mr. Wilson served as the Quality Control Manager at Mayne Pharma where he was responsible for multiple quality control laboratories including drug substance, drug product, raw materials and stability. Mr. Wilson has a Bachelor of Science and Master of Science in Chemistry from East Carolina University.